🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Idiopathic Inflammatory Myopathy (IIM)

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) NCT06350110Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: CD19- BCMA CAR-T cells Adult and Juvenile Myositis NCT00017914n/a4 sites📍 Atlanta📍 Bethesda📍 Research Triangle Park National Institute of Environmental Health Sciences (NIEHS) CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases NCT07315087Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: QT-019C An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases NCT07174843EARLY Phase 11 site📍 Shanghai Shanghai Cell Therapy Group Co.,Ltd · Tests: CD19/CD22/BCMA CAR-T cells(BZE2204) A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) NCT06733935Phase 1, Phase 218 sites📍 Orange📍 Gainesville📍 Miami Nkarta, Inc. · Tests: NKX019, Fludarabine, Cyclophosphamide Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM) NCT07160205Phase 2, Phase 32 sites📍 Gainesville📍 Miami Restem, LLC. · Tests: ULSC (1.5 x 10^8 cells/dose), Placebo (no cells) Optimizing Treatment on Idiopathic Inflammatory Myopathies NCT03092180n/a1 site📍 São Paulo University of Sao Paulo · Tests: Intravenous Infusion A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies NCT06698796Phase 326 sites📍 Glendale📍 Frisco📍 Houston Pfizer · Tests: Dazukibart Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases NCT07085676Phase 11 site📍 Jerusalem Polina Stepensky · Tests: HBI0101 CART GC012F Injection in Refractory Idiopathic Inflammatory Myopathy NCT07086404EARLY Phase 11 site📍 Wuhan Daishi Tian · Tests: GC012F Injection infusion A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) NCT06455449Phase 3237 sites📍 Phoenix📍 Irvine📍 Aurora AstraZeneca · Tests: Anifrolumab (blinded), Placebo, Anifrolumab (unblinded, open label) AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. NCT06991114Phase 252 sites📍 Tuscaloosa📍 Phoenix📍 Tucson Artiva Biotherapeutics, Inc. · Tests: Allogeneic NK Cells A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease NCT06308978Phase 121 sites📍 Beverly Hills📍 Fullerton📍 Irvine Fate Therapeutics · Tests: FT819, Fludarabine, Cyclophosphamide, Bendamustine A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases NCT07115745Phase 128 sites📍 Boston📍 Durham📍 Camperdown Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Tests: BMS-986515, Fludarabine, Cyclophosphamide, Tocilizumab A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] NCT05895786Phase 3138 sites📍 Glendale📍 Phoenix📍 Phoenix Pfizer · Tests: PF-06823859, Placebo A Study of AZD0120 in Autoimmune Diseases NCT07295847Phase 122 sites📍 Tucson📍 Stanford📍 Chicago AstraZeneca · Tests: AZD0120 A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease NCT06925542Phase 117 sites📍 La Jolla📍 Redwood City📍 Chicago CRISPR Therapeutics · Tests: CTX112 A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases NCT06980597Phase 12 sites📍 Beijing📍 Beijing Beijing GoBroad Hospital · Tests: OL-108 A Study of CC312 for Relapsed/Refractory Autoimmune Diseases NCT07193810EARLY Phase 11 site📍 Deyang CytoCares Inc · Tests: CC312 Safety Study of CC312 in Autoimmune Disease Patients NCT06888960EARLY Phase 11 site📍 Tianjin CytoCares Inc · Tests: CC312 A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease NCT07085104Phase 117 sites📍 Phoenix📍 Loma Linda📍 Aurora Allogene Therapeutics · Tests: ALLO-329, Cyclophosphamide, Fludarabine Adult Autoimmune Myopathies (MAIA) NCT04792931NA1 site📍 Brest University Hospital, Brest · Tests: description of adult autoimmune myopathies Follow-up of Patients With Inflammatory Myopathies Associated With a Biobank NCT05454527n/a2 sites📍 Paris📍 Paris Assistance Publique - Hôpitaux de Paris Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases NCT07087912Phase 42 sites📍 São Paulo📍 São Paulo University of Sao Paulo General Hospital · Tests: Dengue 1,2,3,4 (attenuated) vaccine Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases NCT06548607EARLY Phase 11 site📍 Bengbu Nanjing Bioheng Biotech Co., Ltd. · Tests: CD19 or CD19-BCMA CAR-T Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy NCT07103746Phase 28 sites📍 Birmingham📍 Atlanta📍 Chicago National Institute of Allergy and Infectious Diseases (NIAI… · Tests: Ublituximab, Placebo for Ublituximab OM336 in Seropositive Autoimmune Diseases NCT07229144Phase 11 site📍 Hamilton Lakefront Biotherapeutics West LLC · Tests: OM336 Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis NCT06479863EARLY Phase 12 sites📍 Austin📍 Austin Austin Neuromuscular Center · Tests: Pozelimab/Cemdisiran FT839 in Autoimmune Diseases NCT07800871Phase 1, Phase 21 site📍 Fullerton Fate Therapeutics · Tests: FT839 Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases NCT06285539Phase 26 sites📍 Amsterdam📍 Heerlen📍 Nijmegen UMC Utrecht · Tests: Filgotinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy